Sechenov School
Home › Microbiology › Pneumocystosis: Diagnosis and Treatment

Pneumocystosis

Pneumocystis jirovecii

For medical students2 min readUpdated 2026-10-10

Pneumocystosis is an opportunistic fungal infection caused by Pneumocystis jirovecii. Successful patient management relies on precise serological diagnosis, timely targeted antimicrobial therapy, and strict monitoring of high-risk groups.

DiagnosticsIFA and ELISA for specific antibody detection
Drug of choiceTrimethoprim-sulfamethoxazole (TMP-SMX) as the core therapy
TransmissionAerogenic (airborne) route
Risk groupImmunocompromised patients, particularly those with HIV

Serological Diagnosis

Serological methods are widely used for laboratory confirmation. Their main objective is to detect specific antibodies produced by the immune system in response to Pneumocystis jirovecii invasion.

Two primary methods are utilized in modern practice:

A critical step is the accurate interpretation of results. The detection of IgM class immunoglobulins in the patient's blood clearly indicates an acute infection. An alternative criterion for an acute process is the analysis of paired sera: a marked dynamic rise in IgG antibody titers also points to an acute course of the disease.

Principles of Etiotropic Therapy

Treatment of pneumocystosis requires specific antimicrobial agents. The fundamental drug of choice for suppressing the pathogen is trimethoprim-sulfamethoxazole (co-trimoxazole).

When use of the primary drug is contraindicated, clinicians switch to alternative regimens. Reserve options in clinical practice include:

Prophylaxis and Management of Risk Groups

Preventive measures for pneumocystosis have a clear epidemiological focus. Because the pathogen spreads via an aerogenic (airborne) route, all preventive measures focus on interrupting this mode of transmission.

Special clinical attention must be given to high-risk patients. The absolute priority within this category is HIV-infected individuals. A vital component of prophylaxis for these patients is the systemic improvement of their immune status, which reduces the likelihood of developing a manifest form of the disease.

Mnemonic

To remember the alternative drugs, use the acronym "PCP": Pentamidine, Caspofungin, Primaquine (+clindamycin).

Frequently asked questions

To which kingdom and class does Pneumocystis jirovecii belong?

The pathogen Pneumocystis jirovecii belongs to the phylum Ascomycota. Taxonomically, it is classified as an opportunistic yeast-like fungus, though its morphological features and susceptibility to medications share properties with protozoa.

What clinical specimens are used for microscopic diagnosis of pneumocystosis?

Microscopic examination to detect Pneumocystis jirovecii utilizes bronchoalveolar lavage (BAL) fluid, sputum, and lung tissue biopsies.

What morphological forms does Pneumocystis jirovecii exhibit in the human body?

The life cycle and development of the pathogen occur within the alveolar lumen of the lungs and include four main sequential stages:

  • Trophozoite (Trophozoitus) — an oval, amoeboid form measuring 1.5–5 µm, covered by a pellicle and capsule.
  • Pracyst (Praecista) — an intermediate rounding stage with a thickened cell wall.
  • Cyst (Cysta) — a form measuring 4–8 µm with a thick three-layered wall rich in polysaccharides.
  • Intracystic bodies (Corporecula intracystica) — daughter cells (sporozoites) measuring 1–2 µm with a small nucleus and double-layered membrane, forming a "rosette" inside the cyst.
What staining methods are used to identify pneumocystis cysts in smears?

Microscopic staining methods are used to identify the pathogen and its structures in smears. Giemsa staining reveals internal structures, with the cytoplasm staining light blue and the nucleus reddish-purple. To highlight the cyst cell wall, specialized methods are used: toluidine blue staining and Grocott's methenamine silver (GMS) stain, which colors the wall polysaccharides.

What clinical symptoms are characteristic of Pneumocystis pneumonia (PCP)?

The clinical presentation of Pneumocystis pneumonia is characterized by a prominent bronchopulmonary syndrome. Patients typically present with:

  • Persistent dry cough;
  • Progressive dyspnea;
  • Fever;
  • Chest tightness;
  • Tachypnea;
  • Occasionally, frothy sputum.
Which serological markers indicate acute pneumocystosis?

Acute infection is indicated by either the primary detection of IgM antibodies or a dynamic rise in IgG antibody titers in paired sera.

What is the first-line medication prescribed?

The drug of choice for treating pneumocystosis is trimethoprim-sulfamethoxazole (TMP-SMX).

Who is at the highest risk for pneumocystosis?

The primary risk group consists of immunocompromised patients, particularly those with HIV infection and low CD4 counts.

How is the pathogen transmitted?

Pneumocystis jirovecii is transmitted via an aerogenic, or airborne, route.

Go deeper

More topics in Microbiology

Host Reactivity Factors and the Infectious ProcessMicrobiological DiagnosticsAnaplasmosis and EhrlichiosisArenaviruses: Structure, Pathogenesis and Clinical FeaturesPrion DiseasesClassification of Fungal InfectionsCyclosporaBacterial MorphologyBacterial NutritionOpportunistic MicroorganismsPlasmidsHistory of AntibioticsMicrobiology →